Literature DB >> 9079804

Interferon-gamma and interleukin-4 regulate T cell interleukin-12 responsiveness through the differential modulation of high-affinity interleukin-12 receptor expression.

J A Gollob1, H Kawasaki, J Ritz.   

Abstract

Interferon-gamma (IFN-gamma) and interleukin-4 (IL-4) are mutually antagonistic cytokines that stimulate CD4+ T cells to develop into either Th1 or Th2 cells. One feature of Th2 differentiation in mice is the loss of IL-12-induced Jak2 and Stat4 activation, which is accompanied by the inability to produce IFN-gamma in response to IL-12. In this report, we show that freshly isolated human T cells activated with phytohemagglutinin (PHA) in the presence of IL-4 exhibit a greatly diminished response to IL-12, whereas the IL-12 response of T cells activated with PHA plus IFN-gamma is enhanced. Radiolabeled IL-12 binding studies demonstrate that the impairment of T cell IL-12 responsiveness by IL-4 is associated with the down-regulation of high-affinity IL-12 receptor expression. In contrast, the enhancement of IL-12 responsiveness by IFN-gamma is associated with the upregulation of high-affinity IL-12 receptor expression. Through the use of a newly synthesized neutralizing antibody to the low-affinity IL-12 receptor beta subunit (IL-12Rbeta), we show that neither IL-4 nor IFN-gamma affect the expression of IL-12Rbeta, which we determine to be one of at least two low-affinity subunits required for high-affinity IL-12 binding. These findings suggest that IL-4 and IFN-gamma exert opposite effects on T cell IL-12 responsiveness by differentially modulating the expression of low-affinity IL-12 receptor subunits that are distinct from IL-12Rbeta and required, together with IL-12Rbeta, for high-affinity IL-12 binding and IL-12 responsiveness. This provides a basis for understanding the interplay between different cytokines at the level of cytokine receptor expression, and offers insight into one of the mechanisms governing Th1 and Th2 development.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9079804     DOI: 10.1002/eji.1830270311

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  11 in total

Review 1.  IL-12 as a therapeutic target for pharmacological modulation in immune-mediated and inflammatory diseases: regulation of T helper 1/T helper 2 responses.

Authors:  G Haskó; C Szabó
Journal:  Br J Pharmacol       Date:  1999-07       Impact factor: 8.739

2.  Type I cytokine profiles of human naïve and memory B lymphocytes: a potential for memory cells to impact polarization.

Authors:  Alenka Gagro; Drazen Servis; Alma-Martina Cepika; Kai-Michael Toellner; Gillian Grafton; Dale R Taylor; Srecko Branica; John Gordon
Journal:  Immunology       Date:  2006-05       Impact factor: 7.397

3.  The intraperitoneal inoculation of Lactobacillus casei in mice induces total protection against Trichinella spiralis infection at low challenge doses.

Authors:  Federico Martínez-Gómez; Beatriz Eugenia Fuentes-Castro; Carlos Ramón Bautista-Garfias
Journal:  Parasitol Res       Date:  2011-05-04       Impact factor: 2.289

4.  Interleukin-12 is synthesized by mesangial cells and stimulates platelet-activating factor synthesis, cytoskeletal reorganization, and cell shape change.

Authors:  B Bussolati; F Mariano; L Biancone; R Foà; S David; V Cambi; G Camussi
Journal:  Am J Pathol       Date:  1999-02       Impact factor: 4.307

5.  Tumour-induced polarization of tumour vaccine-draining lymph node T cells to a type 1 cytokine profile predicts inherent strong immunogenicity of the tumour and correlates with therapeutic efficacy in adoptive transfer studies.

Authors:  Hauke Winter; Hong-Ming Hu; Christian H Poehlein; Erik Huntzicker; John J Osterholzer; Jaffar Bashy; David Lashley; Bruce Lowe; Jane Yamada; Gregory Alvord; Walter J Urba; Bernard A Fox
Journal:  Immunology       Date:  2003-03       Impact factor: 7.397

6.  Characterization of a novel subset of CD8(+) T cells that expands in patients receiving interleukin-12.

Authors:  J A Gollob; C P Schnipper; E Orsini; E Murphy; J F Daley; S B Lazo; D A Frank; D Neuberg; J Ritz
Journal:  J Clin Invest       Date:  1998-08-01       Impact factor: 14.808

7.  T cell-mediated pathology in two models of experimental colitis depends predominantly on the interleukin 12/Signal transducer and activator of transcription (Stat)-4 pathway, but is not conditional on interferon gamma expression by T cells.

Authors:  S J Simpson; S Shah; M Comiskey; Y P de Jong; B Wang; E Mizoguchi; A K Bhan; C Terhorst
Journal:  J Exp Med       Date:  1998-04-20       Impact factor: 14.307

8.  Interferon consensus sequence binding protein-deficient mice display impaired resistance to intracellular infection due to a primary defect in interleukin 12 p40 induction.

Authors:  T Scharton-Kersten; C Contursi; A Masumi; A Sher; K Ozato
Journal:  J Exp Med       Date:  1997-11-03       Impact factor: 14.307

9.  STAT4 sequence variant and elevated gene expression are associated with type 1 diabetes in Polish children.

Authors:  Marta Fichna; Magdalena Żurawek; Klaudia Bogusz-Górna; Piotr P Małecki; Elżbieta Niechciał; Anna Sidoruk; Katarzyna Furman; Piotr Fichna
Journal:  Cent Eur J Immunol       Date:  2020       Impact factor: 2.085

10.  Interferon-γ derived from cytotoxic lymphocytes directly enhances their motility and cytotoxicity.

Authors:  Purnima Bhat; Graham Leggatt; Nigel Waterhouse; Ian H Frazer
Journal:  Cell Death Dis       Date:  2017-06-01       Impact factor: 8.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.